Business
BBOT to Participate in Upcoming September Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company’s participation are as follows: Cantor Global Healthcare Conference Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in
About this update from Bridgebio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company’s participation are as follows: Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event. About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn . BBOT Contacts: Investor Contact: Uneek Mehra, Chief Financial Officer BBOT [email protected] Media Contact: Jake Robison Inizio Evoke Comms [email protected]
View stock analysis, news, and events for Bridgebio Oncology Therapeutics, Inc.